Outras apresentações
Embora a manifestação mais comum de PDIC típica seja fraqueza simétrica progressiva crônica, os pacientes podem apresentar uma evolução recidivante e remitente ou gradual, que é mais comum com idade de início mais jovem.[3]Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018 Jun;93(6):777-93.
https://www.mayoclinicproceedings.org/article/S0025-6196(18)30236-2/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/29866282?tool=bestpractice.com
[4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30.
http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com
[5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63.
http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com
[6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53.
http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com
A manifestação subaguda ao longo de 4-8 semanas pode dificultar a diferenciação entre polirradiculoneuropatia desmielinizante inflamatória crônica (PDIC) e síndrome de Guillain-Barré.[3]Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018 Jun;93(6):777-93.
https://www.mayoclinicproceedings.org/article/S0025-6196(18)30236-2/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/29866282?tool=bestpractice.com
[5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63.
http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com
[7]Oh SJ, Kurokawa K, de Almeida DF, et al. Subacute inflammatory demyelinating neuropathy. Neurology. 2003 Dec 9;61(11):1507-12.
http://www.ncbi.nlm.nih.gov/pubmed/14663033?tool=bestpractice.com
Uma manifestação monofásica subaguda é mais comum em crianças, adolescentes e adultos jovens, que geralmente respondem bem à terapia imunomoduladora.[8]Nevo Y, Pestronk A, Kornberg AJ, et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology. 1996 Jul;47(1):98-102.
http://www.ncbi.nlm.nih.gov/pubmed/8710133?tool=bestpractice.com
[9]Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle Nerve. 1997 Aug;20(8):1008-15.
http://www.ncbi.nlm.nih.gov/pubmed/9236792?tool=bestpractice.com
Há muitas variantes de PDIC. Pode ocorrer manifestação sensitiva pura, com perda sensitiva distal e dor ou com ataxia sensitiva, mas sem fraqueza muscular. Na PDIC com predominância sensorial, a desmielinização motora é encontrada em estudos eletrodiagnósticos, e pode desenvolver fraqueza à medida que a evolução se cronifica.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
Pacientes com PDIC puramente motora apresentam fraqueza proximal e distal relativamente simétrica, mas sensibilidade normal clinica e eletrodiagnóstica. Deve-se ter cautela ao diferenciar da neuropatia motora multifocal, na qual a fraqueza é assimétrica e afeta principalmente os membros superioes. Corticosteroides podem causar deterioração em pacientes com PDIC motora.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
A PDIC distal (também chamada de neuropatia simétrica desmielinizante adquirida distal) deve ser diferenciada da neuropatia relacionada à glicoproteína associada à mielina.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
[10]Mygland A, Monstad P. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness. Arch Neurol. 2003 Feb;60(2):260-4.
https://jamanetwork.com/journals/jamaneurology/fullarticle/783675
http://www.ncbi.nlm.nih.gov/pubmed/12580713?tool=bestpractice.com
[11]Steck AJ. Anti-MAG neuropathy: from biology to clinical management. J Neuroimmunol. 2021 Dec 15;361:577725.
https://www.jni-journal.com/article/S0165-5728(21)00252-6/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/34610502?tool=bestpractice.com
Além da ausência de fraqueza proximal, essa apresentação difere da PDIC clássica no sentido de que normalmente tem uma proteína monoclonal, a proteína no líquido cefalorraquidiano (LCR) geralmente não é elevada, a evolução raramente é recidivante/remitente e, em geral, há uma resposta inadequada à medicação imunossupressora (quando há presença de proteína monoclonal).[10]Mygland A, Monstad P. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness. Arch Neurol. 2003 Feb;60(2):260-4.
https://jamanetwork.com/journals/jamaneurology/fullarticle/783675
http://www.ncbi.nlm.nih.gov/pubmed/12580713?tool=bestpractice.com
A PDIC que se manifesta com fraqueza assimétrica multifocal e dormência que começa distalmente, normalmente em um membro, e se dissemina em direção proximal para envolver vários membros é chamada de PDIC multifocal (também conhecida como neuropatia desmielinizante multifocal com bloqueio de condução persistente, síndrome de Lewis-Sumner; neuropatia sensorial e motora desmielinizante adquirida multifocal [MADSAM]; neuropatia desmielinizante inflamatória multifocal).[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
[12]Lewis RA, Sumner AJ, Brown MJ, et al. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982 Sep;32(9):958-64.
http://www.ncbi.nlm.nih.gov/pubmed/7202168?tool=bestpractice.com
[13]Saperstein DS, Amato AA, Wolfe GI, et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve. 1999 May;22(5):560-6.
http://www.ncbi.nlm.nih.gov/pubmed/10331353?tool=bestpractice.com
Casos raros podem se manifestar com fraqueza assimétrica e perda sensorial somente nos braços, conhecida como PDIC focal ou neuropatia desmielinizante focal dos membros superiores.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
[14]Thomas PK, Claus D, Jaspert A, et al. Focal upper limb demyelinating polyneuropathy. Brain. 1996 Jun;119 (Pt 3):765-74.
https://academic.oup.com/brain/article/119/3/765/396265
http://www.ncbi.nlm.nih.gov/pubmed/8673489?tool=bestpractice.com